Darzalex showed more positive data in newly-diagnosed patients, while isatuximab was making its phase 3 debut. Darzalex aims to fend off Sanofi’s rival and also improve the patient experience with its subcutaneous formulation.

Kelly Clapp from Kantar reviews the data from the multiple myeloma showdown and provides some thoughts on what it means for the therapy area.